Carlo Magno
Papers
2
Total Citations
71
H-Index
2
About
Dr. Carlo Magno is a leading urologic oncologist whose research focuses on improving the diagnosis and treatment of prostate cancer, with particular expertise in active surveillance protocols and advanced radiotherapy techniques. His seminal 2015 study, cited 50 times, demonstrated that biomarkers PHI and PCA3 significantly enhance the prognostic accuracy of established active surveillance criteria (PRIAS and Epstein) for identifying clinically insignificant prostate cancer—a critical contribution that helps men avoid unnecessary treatment while ensuring dangerous cancers are not missed. In parallel, his pioneering work on high-dose robotic stereotactic body radiotherapy (SBRT), cited 21 times, established this approach as a viable alternative to high-dose-rate brachytherapy for localized prostate cancer, whether as monotherapy or as a boost before external-beam radiotherapy. Dr. Magno’s research bridges the gap between molecular diagnostics and cutting-edge radiation oncology, directly impacting clinical decision-making for thousands of patients. His work has been instrumental in refining risk stratification and expanding treatment options, making him a respected voice in the ongoing effort to personalize prostate cancer care and improve patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1
- 2